Reference : Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Ca...
Scientific congresses and symposiums : Poster
Human health sciences : Oncology
http://hdl.handle.net/2268/157164
Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer : BOLERO-6
English
Ejlertsen, Bent [Copenhagen University Hospital, Copenhagen, Denmark > > > >]
JERUSALEM, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Hurvitz, Sara [UCLA Medical Center, Los Angeles, California, USA > > > >]
de Boer, Richard [Royal Melbourne Hospital, Melbourne, Australia > > > >]
Taran, Tetiana [Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA > > > >]
Sahmoud, Tarek [Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA > > > >]
Burris, Howard [Sarah Cannon Research Institute, Nashville, Tennessee, USA > > > >]
Mar-2013
Yes
International
St. Gallen International Breast Cancer Conference
March 13-16, 2013
St Gallen
Switzerland
[en] The data from this trial will provide insight into the safety and efficacy of the combination of EVE and EXE versus EVE or capecitabine monotherapy in women with ER+, HER2- ABC progressing on/after prior LET or ANA.
http://hdl.handle.net/2268/157164

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
St Gall 2013 poster.pdfPublisher postprint1.43 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.